Orencia® (abatacept) – Expanded indication
March 30, 2017 – The FDA approved Bristol-Myers Squibb’s Orencia (abatacept) injection, for reducing signs and symptoms in patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA).
Download PDF
